Replies to post #2635 on Jaguar Health Inc (JAGX)

[oldstocks]

So we are also expecting results from a study other than the Phase 3 OnTarget Study treating chemo cancer patients.

I did not catch that part below:

Jaguar is supporting investigator-initiated and investigator IND proof-of-concept studies of crofelemer for the rare disease indications of microvillus inclusion disease (MVID) and short bowel syndrome (SBS) with intestinal failure in the US, EU and Middle East/North Africa (MENA) regions, with results expected before the end of 2023 and in 2024. In accordance with the guidelines of specific EU countries, published data from such clinical investigations could support reimbursed early patient access to crofelemer for SBS or MVID for these debilitating conditions.

I knew JAGX had no worries of a reverse split until after May 6th.
We are all banking on good news and good results to get JAGX over $1 before than

[DTGoody]

Thank You TJG and I look forward to seeing what they're reply will be?

I'm going to be on the road for the next day and a half as we are headed back to PA from Texas.